Tag Archives: Celldex

November, 2018

November, 2016

October, 2016

  • 10 October

    Celldex’s Melanoma Candidate Meets Primary Objective in Mid-Stage Study

    HAMPTON, N.J., Oct. 09, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented positive results from the Company’s Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK inhibitor-refractory metastatic melanoma (n=62). Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that …

July, 2016

June, 2016

  • 6 June

    Celldex Presents Positive Results from its Phase II Melanoma Study

    HAMPTON, N.J., June 04, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDX‑1401 and CDX‑301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex …

April, 2016

March, 2016

  • 7 March

    Celldex Discontinues its Late-Stage Brain Cancer Vaccine Study

    HAMPTON, N.J., March 07, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma …

February, 2016